{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:55:47Z","timestamp":1773834947095,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.dsx.2015.10.002","type":"journal-article","created":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T11:36:21Z","timestamp":1445859381000},"page":"S99-S102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S1","title":["Discordance between lipid markers used for predicting cardiovascular risk in patients with type 2 diabetes"],"prefix":"10.1016","volume":"10","author":[{"given":"K.D.","family":"Modi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Chandwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishaq","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.V.S. Hari","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9153","key":"10.1016\/j.dsx.2015.10.002_bib0115","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)07368-1","article-title":"Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study","volume":"353","author":"Gaede","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2015.10.002_bib0120","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus","volume":"329","author":"The Diabetes Control Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dsx.2015.10.002_bib0125","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"Prospective Diabetes Study (UKPDS) U.K. Group","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.dsx.2015.10.002_bib0130","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jama.294.3.326","article-title":"Non-HDL cholesterol, apolipoproteins A\u2013I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women","volume":"294","author":"Ridker","year":"2005","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.dsx.2015.10.002_bib0135","doi-asserted-by":"crossref","first-page":"3K","DOI":"10.1016\/j.amjcard.2005.08.002","article-title":"Reducing residual risk for patients on statin therapy: the potential role of combination therapy","volume":"96","author":"Davidson","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.dsx.2015.10.002_bib0140","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3132\/dvdr.2008.046","article-title":"Residual Risk Reduction Initiative (R3I) The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient","volume":"5","author":"Fruchart","year":"2008","journal-title":"Diab Vasc Dis Res"},{"issue":"15","key":"10.1016\/j.dsx.2015.10.002_bib0145","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.amjcard.2006.07.036","article-title":"Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100mg\/dl","volume":"98","author":"Cromwell","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.dsx.2015.10.002_bib0150","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta-analysis of lowdensity lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.dsx.2015.10.002_bib0155","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0009-9120(03)00117-6","article-title":"Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula","volume":"36","author":"Sniderman","year":"2003","journal-title":"Clin Biochem"},{"key":"10.1016\/j.dsx.2015.10.002_bib0160","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.dsx.2015.10.002_bib0165","first-page":"124","article-title":"Importance of measuring non-HDL cholesterol in type 2 diabetes patients","volume":"64","author":"Ahmed","year":"2014","journal-title":"J Pak Med Assoc"},{"issue":"8","key":"10.1016\/j.dsx.2015.10.002_bib0170","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.2337\/diacare.28.8.1916","article-title":"Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes","volume":"28","author":"Liu","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2015.10.002_bib0175","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III)","volume":"285","author":"Expert Panel on Detection Evaluation Treatment of High Blood Cholesterol in Adults","year":"2001","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.dsx.2015.10.002_bib0180","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc14-S014","article-title":"Standards of medical care in diabetes\u20142014","volume":"37","author":"American Diabetes Association","year":"2014","journal-title":"Diabetes Care"},{"issue":"21","key":"10.1016\/j.dsx.2015.10.002_bib0185","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.jacc.2013.07.045","article-title":"Non-HDL cholesterol, guideline targets, and population percentiles for secondary prevention in a clinical sample of 1.3 million adults The Very Large Database of Lipids (VLDL-2 Study)","volume":"62","author":"Elshazly","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.dsx.2015.10.002_bib0190","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.2337\/diacare.27.8.1991","article-title":"Non-HDL cholesterol and apolipoprotein B predicts cardiovascular disease events among men with type 2 diabetes","volume":"27","author":"Jiang","year":"2004","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.dsx.2015.10.002_bib0195","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1001\/archinte.161.11.1413","article-title":"Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality","volume":"161","author":"Cui","year":"2001","journal-title":"Arch Intern Med"},{"issue":"Oct (4)","key":"10.1016\/j.dsx.2015.10.002_bib0200","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1016\/j.ijcard.2013.06.023","article-title":"Relevance of intermediate-density lipoprotein cholesterol to Framingham risk score of coronary heart disease in middle-aged men with increased non-HDL cholesterol","volume":"168","author":"Ito","year":"2013","journal-title":"Int J Cardiol"},{"issue":"Oct (8 Suppl)","key":"10.1016\/j.dsx.2015.10.002_bib0205","first-page":"S3","article-title":"Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting","volume":"14","author":"Cziraky","year":"2008","journal-title":"J Manage Care Pharm"},{"issue":"May (3)","key":"10.1016\/j.dsx.2015.10.002_bib0210","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4103\/2230-8210.131134","article-title":"Role of glitazars in atherogenic dyslipidemia and diabetes: two birds with one stone?","volume":"18","author":"Munigoti","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"issue":"Jun (1)","key":"10.1016\/j.dsx.2015.10.002_bib0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2014.04.001","article-title":"The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice","volume":"15","author":"Sattar","year":"2014","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.dsx.2015.10.002_bib0220","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation"}],"container-title":["Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402115300503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402115300503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T03:55:39Z","timestamp":1537242939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402115300503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1871402115300503"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2015.10.002","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discordance between lipid markers used for predicting cardiovascular risk in patients with type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2015.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}